iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Q4FY22 Preview: Dr. Reddy's Laboratories: Revenues seen at Rs50,746 million, PAT at Rs6,253 million

18 May 2022 , 07:51 AM

Result date: 19th May, 2022
Recommendation: Buy
Target price: Rs5,000

Dr. Reddy’s Laboratories (Dr. Reddy’s) could witness 3% sequential growth in its US revenues during the March 2022 quarter. It has captured ~13.5% market share in Vascepa during the quarter under review, up from ~9% in December 2021, i.e. its market share has almost trebled from ~4.5% in the June 2022 quarter. According to IU data, Dr. Reddy’s launched Vasostrict AG in February 22 and has garnered ~8% market share in the Vasostrict injectable vials market. This product will be key to the growth of US revenues during the quarter.

The company’s revenue could grow 7%, EBITDA 8% and Profit After Tax (PAT) 15% as compared to the year-ago quarter.

Important management insights to watch out for:
·         Outlook on the generic API business
·         New launch pipeline
·         Likely full contribution from new launches
·         Strategy to gain market share
 

Rs Million March 2022 estimates YoY change QoQ change
Revenue 50,746 7% (5)%
EBITDA 10,915 8% (9)%
Profit After Tax 6,253 15% (12)%

Source: IIFL Research

Related Tags

  • Dr Reddys
  • Dr Reddys Lab
  • Dr Reddys Laboratories
  • Dr. Reddys Labs
  • DRL
  • March 2022 quarter
  • Q4FY22
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.